Ascrinvacumab: Difference between revisions
CSV import |
CSV import |
||
| (One intermediate revision by the same user not shown) | |||
| Line 51: | Line 51: | ||
{{medicine-stub}} | {{medicine-stub}} | ||
{{No image}} | |||
__NOINDEX__ | |||
Latest revision as of 02:48, 17 March 2025
Experimental monoclonal antibody
| Ascrinvacumab | |
|---|---|
| [[File:|frameless|220px|alt=|]] | |
| INN | |
| Drug class | |
| Routes of administration | |
| Pregnancy category | |
| Bioavailability | |
| Metabolism | |
| Elimination half-life | |
| Excretion | |
| Legal status | |
| CAS Number | |
| PubChem | |
| DrugBank | |
| ChemSpider | |
| KEGG | |
Ascrinvacumab is an experimental monoclonal antibody (mAb) that is being investigated for its potential therapeutic applications. Monoclonal antibodies are antibodies that are made by identical immune cells that are all clones of a unique parent cell. They can be designed to target specific cells or proteins, making them useful in the treatment of various diseases, including cancer, autoimmune diseases, and infectious diseases.
Mechanism of Action[edit]
Ascrinvacumab works by targeting a specific antigen found on the surface of certain cells. By binding to this antigen, the antibody can either directly inhibit the function of the target cell or mark it for destruction by other components of the immune system. The exact mechanism of action for ascrinvacumab is still under investigation, but it is believed to involve the modulation of immune responses.
Clinical Trials[edit]
Ascrinvacumab is currently undergoing clinical trials to evaluate its safety and efficacy. These trials are essential for determining the potential therapeutic benefits and risks associated with the drug. The results of these trials will determine whether ascrinvacumab can be approved for use in clinical practice.
Potential Applications[edit]
The primary focus of research on ascrinvacumab is its application in the treatment of various types of cancer. Monoclonal antibodies like ascrinvacumab can be used to target cancer cells specifically, reducing the impact on healthy cells and minimizing side effects. Additionally, there is ongoing research into its potential use in treating autoimmune diseases and infectious diseases.
Side Effects[edit]
As with any therapeutic agent, ascrinvacumab may have side effects. Common side effects associated with monoclonal antibodies include infusion reactions, allergic reactions, and immunosuppression. The specific side effects of ascrinvacumab will be better understood as clinical trials progress.
See Also[edit]
References[edit]
<references group="" responsive="1"></references>
